{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"53.1","value":"571.5"},{"groupId":"OG001","spread":"58.7","value":"535.0"},{"groupId":"OG002","spread":"58.2","value":"708.0"},{"groupId":"OG003","spread":"37.4","value":"495.5"},{"groupId":"OG004","spread":"39.8","value":"543.3"},{"groupId":"OG005","spread":"56.2","value":"439.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"8"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"47.9","value":"1913"},{"groupId":"OG001","spread":"112.9","value":"1998"},{"groupId":"OG002","spread":"36.1","value":"2907"},{"groupId":"OG003","spread":"20.8","value":"3703"},{"groupId":"OG004","spread":"75.4","value":"1101"},{"groupId":"OG005","spread":"51.5","value":"3183"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"8"}],"units":"Participants"}],"description":"Maximum plasma concentration (Cmax) for FT-2102 is presented.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with AML or MDS received single agent FT-2102 orally QD in 28-day cycles at dose level of 100 mg until MTD or MED achieved.","id":"OG000","title":"Phase 1: FT-2102 100 mg QD (Single Agent)"},{"description":"Participants with AML or MDS received single agent FT-2102 orally QD in 28-day cycles at dose levels of 150 mg until MTD or MED achieved.","id":"OG001","title":"Phase 1: FT-2102 150 mg QD (Single Agent)"},{"description":"Participants with AML or MDS received single agent FT-2102 orally QD in 28-day cycles at dose levels of 300 mg until MTD or MED achieved.","id":"OG002","title":"Phase 1: FT-2102 300 mg QD (Single Agent)"},{"description":"Participants with AML or MDS received single agent FT-2102 orally BID in 28-day cycles at dose levels of 150 mg until MTD or MED achieved.","id":"OG003","title":"Phase: FT-2102 150 mg BID (Single Agent)"},{"description":"Participants with AML or MDS received combination therapy (FT-2102 + azacitidine 75 mg/m\\^2) orally QD in 28-day cycles at dose levels of 150 mg until MTD or MED achieved","id":"OG004","title":"Phase 1: FT-2102 150 mg QD+Azacitidine (Combination Therapy)"},{"description":"Participants with AML or MDS received combination therapy (FT-2102 + azacitidine 75 mg/m\\^2) orally BID in 28-day cycles at dose levels of 150 mg until MTD or MED achieved.","id":"OG005","title":"Phase 1: FT-2102 150 mg BID+Azacitidine (Combination Therapy)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set included those participants for whom it was possible to calculate at least 1 primary PK parameter and who had no major protocol deviations thought to influence the absorption, distribution, metabolism, and excretion of the FT-2102. Here, number anaylzed (n) = participants with available data for specific timepoints.","reportingStatus":"POSTED","timeFrame":"Phase 1: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)","title":"Phase 1: Maximum Plasma Concentration (Cmax) for FT-2102","type":"SECONDARY","unitOfMeasure":"Nanograms per millilitre (ng/mL)"}